April 3, 2025
FDA grants fast track status to Biogen’s BIIB080 for Alzheimer’s
Biogen has received fast track designation from the US Food and Drug Administration (FDA) for its investigational antisense oligonucleotide (ASO) therapy, BIIB080, to treat Alzheimer's disease.